Stem: Citron's Price Target And Renewable Energy Expansion (NYSE:STEM)
seekingalpha.com
news
2022-10-20 18:46:16

Pixelci/iStock via Getty Images Citron Research almost a year into the pandemic released a bullish research note on Stem (NYSE:STEM). Led by Andrew Left, the infamous short-selling outfit had made a name for itself a few years prior with a report that catalyzed the collapse of Bill Ackman-backed Valeant Pharmaceuticals, now called Bausch Health (BHC). It was a rare bullish research note for a firm that had spent most of its history calling out numerous stock tickers loved by retail investors. Citron's Stem note ascribed a $100 price target and called the company an 800-pound gorilla in a global energy storage market set to be a $1.
